SCHEMBL5322252

SCHEMBL5322252

FC(F)(F)c1ccc(-n2ccc(CN3CCC(c4ccc(Cl)cc4)CC3)c2)cc1

nearest known ligand 0.60

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 1/20 0.60
MCHR1 Q99705 19/20 0.57
KCNH2 Q12809 10/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5316616 0.81 MCHR1 (0.59) MCHR1KCNH2
Hydrochloric Acid SCHEMBL4923401 0.80 MCHR1 (0.58) MCHR1KCNH2
SCHEMBL5316462 0.77 MCHR1 (0.65) MCHR1KCNH2
SCHEMBL5316753 0.77 MCHR1 (0.53) DRD4MCHR1KCNH2
Chlorolithium SCHEMBL4922637 0.77 MCHR1 (0.62) MCHR1KCNH2
Hydrochloric Acid SCHEMBL27710070 0.76 MCHR1 (0.63) MCHR1KCNH2
SCHEMBL5316946 0.76 MCHR1 (0.72) MCHR1KCNH2
Chlorolithium SCHEMBL4927349 0.75 MCHR1 (0.68) MCHR1KCNH2
Chlorolithium SCHEMBL4927355 0.75 MCHR1 (0.68) MCHR1KCNH2
SCHEMBL4915641 0.75 MCHR1 (0.56) MCHR1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1831194-A1 HETEROCYCLIC MCHr1 ANTAGONISTS AND THEIR USE IN THERAPY AstraZeneca AB (SE) 2007-09-12 EP disclosed
WO-2006068594-A1 HETEROCYCLIC MCHr1 ANTAGONISTS AND THEIR USE IN THERAPY ASTRAZENECA AB (SE) 2006-06-29 WO disclosed